Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of …
R Williams, R Aspinall, M Bellis, G Camps-Walsh… - The Lancet, 2014 - thelancet.com
Executive summary Liver disease in the UK stands out as the one glaring exception to the
vast improvements made during the past 30 years in health and life expectancy for chronic …
vast improvements made during the past 30 years in health and life expectancy for chronic …
The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for …
NK Martin, P Vickerman, GJ Dore… - Current opinion in HIV …, 2015 - journals.lww.com
The hepatitis C virus epidemics in key populations (includin... : Current Opinion in HIV and AIDS
The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners …
The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners …
Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study
Summary Background Hepatitis C virus (HCV) is a leading cause of liver-related morbidity
and mortality worldwide. In the European Union (EU), treatment and cure of HCV with direct …
and mortality worldwide. In the European Union (EU), treatment and cure of HCV with direct …
[HTML][HTML] Prioritization of HCV treatment in the direct-acting antiviral era: an economic evaluation
Background & Aims We determined the optimal HCV treatment prioritization strategy for
interferon-free (IFN-free) HCV direct-acting antivirals (DAAs) by disease stage and risk …
interferon-free (IFN-free) HCV direct-acting antivirals (DAAs) by disease stage and risk …
[HTML][HTML] Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe
H Fraser, NK Martin, H Brummer-Korvenkontio… - Journal of …, 2018 - Elsevier
Background & Aims Prevention of hepatitis C virus (HCV) transmission among people who
inject drugs (PWID) is critical for eliminating HCV in Europe. We estimated the impact of …
inject drugs (PWID) is critical for eliminating HCV in Europe. We estimated the impact of …
[HTML][HTML] Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs
ABSTRACT Background & Aims Scale-up of highly-effective direct-acting antivirals (DAAs)
for hepatitis C virus (HCV) among people who inject drugs (PWID) in Scotland has led to a …
for hepatitis C virus (HCV) among people who inject drugs (PWID) in Scotland has led to a …
Hepatitis C treatment as prevention: evidence, feasibility, and challenges
The advent of interferon-free direct-acting antiviral therapy for hepatitis C virus (HCV)
infection has heightened discussion of treatment as prevention. Rapid scale-up in many …
infection has heightened discussion of treatment as prevention. Rapid scale-up in many …
Hepatitis C: Is eradication possible?
A Lombardi, MU Mondelli… - Liver …, 2019 - Wiley Online Library
Hepatitis C has a relevant global impact in terms of morbidity, mortality and economic costs,
with more than 70 million people infected worldwide. In the resolution,“Transforming our …
with more than 70 million people infected worldwide. In the resolution,“Transforming our …
[HTML][HTML] Management of acute HCV infection in the era of direct-acting antiviral therapy
The management of acute HCV infection has not been standardized following the
availability of direct-acting antiviral agents (DAAs) for chronic HCV infection, and substantial …
availability of direct-acting antiviral agents (DAAs) for chronic HCV infection, and substantial …
Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum
JP Meyer, Y Moghimi, R Marcus, JK Lim… - International Journal of …, 2015 - Elsevier
Background With the explosion of newly available direct acting antiviral (DAA) Hepatitis C
virus (HCV) treatments that demonstrate 95% sustained virologic response (SVR) rates …
virus (HCV) treatments that demonstrate 95% sustained virologic response (SVR) rates …